Boston Scientific Co. (NYSE:BSX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Boston Scientific Co. (NYSE:BSX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-three research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, twenty have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $97.26.

Several analysts have commented on the stock. Mizuho boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Morgan Stanley upped their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a report on Thursday, October 24th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Friday. Truist Financial increased their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, December 16th.

Boston Scientific Trading Down 0.8 %

Shares of NYSE:BSX opened at $95.14 on Monday. Boston Scientific has a 12-month low of $59.39 and a 12-month high of $97.13. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $140.22 billion, a P/E ratio of 78.63, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80. The firm has a fifty day moving average of $89.96 and a two-hundred day moving average of $83.89.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The business's quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities analysts expect that Boston Scientific will post 2.46 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. The trade was a 93.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares of the company's stock, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 29,989 shares of company stock valued at $2,702,261. Company insiders own 0.50% of the company's stock.

Institutional Trading of Boston Scientific

Several hedge funds have recently modified their holdings of BSX. CRA Financial Services LLC increased its holdings in Boston Scientific by 4.3% during the 3rd quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider's stock valued at $238,000 after purchasing an additional 117 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of Boston Scientific by 9.7% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock valued at $115,000 after buying an additional 119 shares in the last quarter. Adero Partners LLC raised its holdings in shares of Boston Scientific by 3.6% in the third quarter. Adero Partners LLC now owns 3,617 shares of the medical equipment provider's stock valued at $303,000 after buying an additional 127 shares during the last quarter. Ashton Thomas Securities LLC lifted its position in Boston Scientific by 1.3% during the 3rd quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider's stock worth $835,000 after buying an additional 129 shares in the last quarter. Finally, Jacobsen Capital Management grew its holdings in Boston Scientific by 4.9% during the 3rd quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider's stock worth $236,000 after acquiring an additional 133 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.